Komo Biosciences
Developer of next-generation targeted gene integration technology based on evolved serine integrases. The company commercializes non-viral, non-nuclease methods for precise insertion of large DNA payloads into predefined genomic loci, and provides proprietary cell-line platforms and licensing to support biologics manufacturing, cell and gene therapy development, and related applications.
Industries
Nr. of Employees
small (1-50)
Products
Integrase-driven cell line platform for high-efficiency insertion
Proprietary engineered mammalian cell lines and platform technologies that enable targeted, high-efficiency insertion of large transgenes into predefined genomic sites to support biologics production and cell therapy development.
Targeted gene integration technology platform
A non-viral, non-nuclease genome engineering platform based on evolved integrases to enable precise, reproducible insertion of large DNA payloads into human and industrial cell lines.
Integrase-driven cell line platform for high-efficiency insertion
Proprietary engineered mammalian cell lines and platform technologies that enable targeted, high-efficiency insertion of large transgenes into predefined genomic sites to support biologics production and cell therapy development.
Targeted gene integration technology platform
A non-viral, non-nuclease genome engineering platform based on evolved integrases to enable precise, reproducible insertion of large DNA payloads into human and industrial cell lines.
Services
Provision of research licenses and partnership arrangements to grant external organizations access to proprietary targeted gene integration technology and engineered cell lines.
Provision of research licenses and partnership arrangements to grant external organizations access to proprietary targeted gene integration technology and engineered cell lines.
Expertise Areas
- Precision genome engineering
- Directed evolution and enzyme engineering
- Cell line development
- Biologics and advanced therapies manufacturing
Key Technologies
- Serine integrase-mediated site-specific recombination
- Directed evolution
- Large DNA payload integration (7–15 kb)
- Non-viral, non-nuclease genome engineering
News & Updates
Announcement of a research license agreement with an external developer to provide access to the targeted insertion gene editing platform. Reported broad media pickup.
Announcement of a board appointment to support strategic growth and leadership in biomanufacturing.
Company emergence from stealth following publication describing non-nuclease, integrase-based insertion of large genes with reported up to 80% integration efficiency per chromosome and high per-cell integration rates.
Peer-reviewed publication describing directed evolution of integrases enabling site-specific insertion of large transgenes.
Announcement of a research license agreement with an external developer to provide access to the targeted insertion gene editing platform. Reported broad media pickup.
Announcement of a board appointment to support strategic growth and leadership in biomanufacturing.
Company emergence from stealth following publication describing non-nuclease, integrase-based insertion of large genes with reported up to 80% integration efficiency per chromosome and high per-cell integration rates.
Peer-reviewed publication describing directed evolution of integrases enabling site-specific insertion of large transgenes.